MCM6 welcomes inquiries from collaborators and investors. We are developing treatments for Alzheimer’s disease in APOE4 carriers, led by an experienced team, secured STTR Phase 1 and Phase 2 funding, and using cutting-edge technology, miBRAIN, our 3-D multicellular human brain iPS cells platform, to discover therapeutic agents.

Contact us to discuss partnership or investment opportunities.